Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT05067621 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of semaglutide in adolescents who are obese and have prediabetes, newly diagnosed type 2 diabetes, or fatty liver disease.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 60 people

Who can join Ages 10–21 · all sexes

Timeline Started 2023-07 · est. completion 2027-01

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05067621 ↗

Description as written by the study sponsor.

The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.

Treatments tested

Semaglutide Pen Injector also known as Wegovy Drug

Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
Placebo Drug

Injection pen contains excipients.

Main thing measured	Change in Oral Disposition Index (oDI)
Sponsor	Yale University
Conditions studied	Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05067621 ↗